For example, poor response to CDK4/6 inhibitors has been observed in patients with coexisting FGFR1 amplification in hormone receptor-positive breast cancer [184] and dual HER2-targeted therapy in HER2-positive breast cancer [136]. Here, CDK4 is linked to breast cancer.